Angina unstable – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:16:15 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Angina unstable – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Semaglutide for Diabetic Patients with Heart Attack or Unstable Angina to Measure Changes in Coronary Artery Plaque Using Imaging https://clinicaltrials.eu/trial/a-study-of-semaglutide-for-diabetic-patients-with-heart-attack-or-unstable-angina-to-measure-changes-in-coronary-artery-plaque-using-imaging/ Wed, 29 Apr 2026 15:08:23 +0000 https://clinicaltrials.eu/trial/a-study-of-semaglutide-for-diabetic-patients-with-heart-attack-or-unstable-angina-to-measure-changes-in-coronary-artery-plaque-using-imaging/ This study involves people who have diabetes mellitus and have experienced a specific type of heart problem called non-ST-elevation myocardial infarction, which is a type of heart attack, or unstable angina, which is chest pain that occurs when the heart does not get enough blood. These conditions happen when the arteries that supply blood to the heart become narrowed or blocked by fatty deposits called plaques. The study will use a medication called semaglutide, which is given as tablets taken by mouth. This medication is normally used to help control blood sugar levels in people with diabetes.

The purpose of this study is to see if semaglutide can reduce inflammation inside the plaques that build up in the heart arteries. Inflammation is a process where the body’s immune system responds to damage or disease, and in this case, certain immune cells called macrophages collect in the plaques. The study will measure whether the medication can decrease the amount of these macrophages in the plaques. To do this, doctors will use a special imaging technique called optical coherence tomography, which is a way of taking detailed pictures of the inside of the arteries using light waves. This procedure allows doctors to see the structure and composition of the plaques.

During the study, participants will receive either semaglutide or a placebo for 24 weeks. At the beginning and end of this period, doctors will perform optical coherence tomography to examine the plaques in the arteries that are not the main blocked artery that caused the heart problem. The study will look at various features of these plaques, including their size, thickness of the covering layer, and the presence of different materials like fat and calcium. Doctors will also monitor blood sugar control, body weight, any heart-related events, and any side effects that may occur during the treatment period.

]]>